← Back to headlines
H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics
H.C. Wainwright has reaffirmed its 'Buy' rating for Structure Therapeutics (GPCR), signaling continued confidence in the company's stock performance.
17 Jun, 15:55 — 17 Jun, 15:55
Sources
Showing 1 of 1 sources
